Cargando…

416: Expression of SARS-CoV-2 entry genes is not greater in the nasal mucosa of CF patients

Detalles Bibliográficos
Autores principales:	Sala, M., Markov, N., Misharin, A., Jain, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Cystic Fibrosis Society. 2021
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518432/ http://dx.doi.org/10.1016/S1569-1993(21)01840-3

Ejemplares similares

Expression of ACE2—a Key SARS-CoV-2 Entry Factor—Is Not Increased in the Nasal Mucosa of People with Cystic Fibrosis
por: Sala, Marc A., et al.
Publicado: (2022)

Immune response to SARS-CoV-2 in the nasal mucosa in children and adults
por: Koch, Clarissa M, et al.
Publicado: (2021)

496: Reduced susceptibility of mice with CF-like lung disease to SARS-CoV-2 infection
por: Hawkins, P., et al.
Publicado: (2021)

Age-related Differences in the Nasal Mucosal Immune Response to SARS-CoV-2
por: Koch, Clarissa M., et al.
Publicado: (2021)

Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection
por: Li, Heng, et al.
Publicado: (2022)

515: Pathways balancing SARS-COV-2 infectivity and disease severity in CF
por: Nakano, S., et al.
Publicado: (2021)

416. Comparative Analytical Assessment of PCR Mastermixes for Detection of SARS-CoV-2 using the CDC Diagnostic Test and the LightMix Modular Test on the cobas® z 480 Analyzer
por: Cagas, Steven, et al.
Publicado: (2020)

410: Pseudomonas aeruginosa modulates SARS-CoV-2 infectivity in CF airway epithelial cells by increasing expression of the host protease TMPRSS2
por: Ruffin, M., et al.
Publicado: (2021)

335: Greater access to mental health care with CF team psychologist through telemedicine during COVID-19
por: Filigno, S., et al.
Publicado: (2021)

P072 SARS-CoV-2 infection in patients with cystic fibrosis (CF) - a single centre experience
por: Vidoevska, A., et al.
Publicado: (2022)

The nasal symbiont Staphylococcus species restricts the transcription of SARS-CoV-2 entry factors in human nasal epithelium
por: Ji, Jeong-Yeon, et al.
Publicado: (2021)

416. Diagnostic Yield of Serial COVID-19 Testing in Hospitalized Patients
por: Li, Jeremy, et al.
Publicado: (2021)

Evidence of SARS-CoV-2 in nasal brushings and olfactory mucosa biopsies of COVID-19 patients
por: Pipolo, Carlotta, et al.
Publicado: (2022)

492: CF innate immune defect affects CF intestinal microbiota
por: Scull, C., et al.
Publicado: (2021)

Expression profile of SARS‐CoV‐2 cellular entry proteins in normal oral mucosa and oral squamous cell carcinoma
por: Sapkota, Dipak, et al.
Publicado: (2021)

Cell entry by SARS-CoV-2
por: Peng, Ruchao, et al.
Publicado: (2021)

Clotting and SARS-CoV-2 entry
por: Hofer, Ursula
Publicado: (2022)

433: Rationale and design of an international multicenter prospective study to evaluate serologic immune responses to SARS-CoV-2 infection in persons living with cystic fibrosis: The CAR-CF study
por: Hernandez, R., et al.
Publicado: (2021)

The R416 Cerenkov counters
por: Meyer, W T
Publicado: (1980)

FRI416 Primary Hyperaldosteronism in Pregnancy
por: Seav, Susan M, et al.
Publicado: (2023)

432. High concordance between self-collected nasal swabs and saliva samples for detection of SARS-CoV-2
por: Grijalva, Carlos G, et al.
Publicado: (2020)

Smoking modulates different secretory subpopulations expressing SARS-CoV-2 entry genes in the nasal and bronchial airways
por: Xu, Ke, et al.
Publicado: (2022)

Smoking Modulates Different Secretory Subpopulations Expressing SARS-CoV-2 Entry Genes in the Nasal and Bronchial Airways
por: Xu, Ke, et al.
Publicado: (2021)

Cell entry mechanisms of SARS-CoV-2
por: Shang, Jian, et al.
Publicado: (2020)

SARS-CoV-2, Early Entry Events
por: Chambers, James P., et al.
Publicado: (2020)

Mechanisms of SARS-CoV-2 entry into cells
por: Jackson, Cody B., et al.
Publicado: (2021)

Postmortem Stability of SARS-CoV-2 in Nasopharyngeal Mucosa
por: Heinrich, Fabian, et al.
Publicado: (2021)

Status report on experiment R416
por: Burlaud, P, et al.
Publicado: (1978)

SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways
por: Sungnak, Waradon, et al.
Publicado: (2020)

SARS-CoV-2 entry factors are expressed in nasal, ocular, and oral tissues: implications for COVID-19 prophylaxes/therapeutics
por: Lee, Ivan, et al.
Publicado: (2021)

Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV
por: V. K., Priya, et al.
Publicado: (2021)

The early SARS-CoV-2 epidemic in Senegal was driven by the local emergence of B.1.416 and the introduction of B.1.1.420 from Europe
por: Perez, Lester J, et al.
Publicado: (2022)

ePS4.01 The impact of the SARS-CoV-2 pandemic on people with cystic fibrosis (CF) in Ireland: did individuals maintain their key health outcomes?
por: Rees, H., et al.
Publicado: (2022)

Surface vimentin is critical for the cell entry of SARS-CoV
por: Yu, Yvonne Ting-Chun, et al.
Publicado: (2016)

Tumor markers as an entry for SARS‐CoV‐2 infection?
por: Xia, Pu, et al.
Publicado: (2020)

Entry, egress and vertical transmission of SARS-CoV-2
por: Zhang, Hui, et al.
Publicado: (2021)

Role of host factors in SARS-CoV-2 entry
por: Evans, John P., et al.
Publicado: (2021)

Contribution of Syndecans to the Cellular Entry of SARS-CoV-2
por: Hudák, Anett, et al.
Publicado: (2021)

Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors
por: Huang, Li, et al.
Publicado: (2022)

Roles of host proteases in the entry of SARS-CoV-2
por: Zabiegala, Alexandria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l5gaif5jbvr6tcpgl56t4huld1